Navigation Links
EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus
Date:12/9/2013

The European Association for the Study of the Liver (EASL) today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection (HCV) (1). The EASL guidelines, which supersede the previous version published in 2011, are designed to help physicians and other healthcare providers optimise their management of patients with acute and chronic HCV.

It is estimated that approximately 160 million individuals, i.e. 2.35% of the world's population, are chronically infected with HCV. In the European Union alone, between 7.3 and 8.8 million people are infected with HCV, double the previous estimate made in 1997. The prevalence varies across the region with higher rates seen in the south and the east, making HCV a critical area of attention for hepatologists as one fifth of HCV-infected patients are at risk of developing cirrhosis or liver cancer (2).

HCV CPG co-chair reviewer and consultant hepatologist at Queen Elizabeth Hospital, Birmingham, Professor David Mutimer said: "As our understanding of HCV increases and therapies evolve, more complex treatment strategies are necessary to achieve the primary goal of curing the infection.

"Since EASL published the last HCV CPG in 2011, two protease inhibitors have been approved for use in patients infected with HCV genotype 1. These first-generation direct-acting antivirals are the first of many direct acting antiviral drugs which will revolutionise treatment for HCV patients, including those who failed to respond to previous therapies. The new guidelines provide essential information on the recommended use of these newly licensed drugs to help prescribers deliver optimal care for their HCV patients."

Based on a systematic review of existing literature, the CPGs provide best practice recommendations on a number of key areas:

  • Current standard of care and developing therapies
  • Diagnosis of acute and chronic hepatitis C
  • Goals and endpoints of HCV therapy
  • Indications for treatment and who should be treated
  • Treatment strategies for different viral genotypes
  • Treatment monitoring including virological response-guided triple, and dual therapy
  • Monitoring treatment safety
  • Treatment of special groups including HIV co-infection, hepatitis B co-infection and patients with other co-morbidities such as severe liver disease

The guidelines also contain significant discussion about people who inject drugs (PWID*) providing an overview of the published literature relating to the treatment of these patients, and covering issues such as:

  • Re-infection following successful HCV treatment in patients at high risk (such as PWID)
  • The burden of chronic HCV and advanced liver disease among ageing cohorts of PWID

Professor Mutimer added: "With HCV spread among PWID now accounting for the vast majority of incident cases in developed countries, and with modelling studies suggesting that treatment for PWID could reduce transmission, it is critical that physicians review and adopt these guidelines when managing this important group of patients."

Commenting on the CPGs, EASL Secretary General Professor Markus Peck-Radosavljevic said "EASL is dedicated to promoting hepatology research and education to improve the worldwide treatment of liver disease. As treatment for hepatitis C continues to progress rapidly with the development and approval of new therapies, it's vital to ensure that our series of Clinical Practice Guidelines reflect best practice to drive better clinical outcomes.

"As there have been several key clinical and scientific advances over the past two years, these guidelines build upon the recommendations reported by the EASL HCV panel of experts in 2011. EASL encourage clinicians to refer to these new HCV guidelines for the most up-to-date, evidence based methods to offer patients first class treatment."


'/>"/>

Contact: Courtney Lock
easlpressoffice@cohnwolfe.com
44-207-331-5317
European Association for the Study of the Liver
Source:Eurekalert  

Related biology news :

1. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
2. Elseviers Maturitas publishes position statement on fertility preservation
3. Genetics in Medicine publishes special issue dedicated to genomics in electronic health records
4. Journal of Spinal Cord Medicine publishes special issue on assistive technology
5. American Academy of Microbiology publishes West Nile virus report
6. Reproductive BioMedicine Online publishes study on assisted reproduction
7. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
8. Leading RSV researcher publishes work at Le Bonheur Childrens
9. PeerJ publishes its first articles
10. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
11. Professor publishes on first-ever imaging of cells growing on spherical surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... CytRx Corporation (NASDAQ: CYTR ), ... today announced the appointment of Earl Warren Brien ... private healthcare investor, to its Board of Directors. ... and strategic experience at the highest level," said ... one of the world,s leading orthopedic surgeons, Dr. Brien ...
(Date:12/2/2016)... ... 01, 2016 , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ), representing ... its chain-of-custody solution for tracking and securing medications at booth 676 at the ... , Aerocom has a proven solution for tracking medications via its system from ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a Chicago-based medical device ... Class II 510(k) clearance for their flagship medical device, SimplECG. , With this ... devices that rely on cloth-based nanosensors. While other companies have attempted to focus ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
Breaking Biology Technology: